P377: A PHASE II TRIAL OF MINI-HYPER-CVD WITH VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA CHROMOSOME (PH)-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

• Fadi Haddad,
• Elias Jabbour,
• Marianne Zoghbi,
• Nicholas Short,
• Jayastu Senapati,
• Walid Macaron,
• Cedric Nasnas,
• Lewis Nasr,
• Naveen Pemmaraju,
• Nitin Jain,
• William G. Wierda,
• Gautam Borthakur,
• Guillermo Montalban-Bravo,
• Farhad Ravandi,
• Guillermo Garcia-Manero,
• Tapan Kadia,
• Kelly Chien,
• Jennifer Thankachan,
• Rebecca Garris,
• Hagop Kantarjian

Affiliations

Fadi Haddad

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Elias Jabbour

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Marianne Zoghbi

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Nicholas Short

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Jayastu Senapati

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Walid Macaron

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Cedric Nasnas

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Lewis Nasr

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Naveen Pemmaraju

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Nitin Jain

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

William G. Wierda

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Gautam Borthakur

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Guillermo Montalban-Bravo

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Farhad Ravandi

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Guillermo Garcia-Manero

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Tapan Kadia

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Kelly Chien

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Jennifer Thankachan

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Rebecca Garris

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States

Hagop Kantarjian

1 The University of Texas MD Anderson Cancer Center, Leukemia, Houston, United States